These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 36860686)

  • 1. Association between daidzein intake and metabolic associated fatty liver disease: A cross-sectional study from NHANES 2017-2018.
    Yang Z; Gong D; He X; Huang F; Sun Y; Hu Q
    Front Nutr; 2023; 10():1113789. PubMed ID: 36860686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Inverse Association Between Isoflavone Intake and Prevalence of Metabolic Syndrome: A Cross-Sectional Study from National Health and Nutrition Examination Survey.
    Yuan F; Zeng Q; Hu Y; Liang J
    Metab Syndr Relat Disord; 2024 Mar; 22(2):97-104. PubMed ID: 37944109
    [No Abstract]   [Full Text] [Related]  

  • 3. Associations between dietary flavonoid intake with hepatic steatosis and fibrosis quantified by VCTE: Evidence from NHANES and FNDDS.
    Xie R; Zhang Y
    Nutr Metab Cardiovasc Dis; 2023 Jun; 33(6):1179-1189. PubMed ID: 36964061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between flavonoid and subclasses intake and metabolic associated fatty liver disease in U.S. adults: Results from National Health and Nutrition Examination Survey 2017-2018.
    Tong J; Zeng Y; Xie J; Xiao K; Li M; Cong L
    Front Nutr; 2022; 9():1074494. PubMed ID: 36532560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Healthy Eating Index-2015 in relation to risk of metabolic dysfunction-associated fatty liver disease among US population: National Health and Nutrition Examination Survey 2017-2018.
    Zhang W; Wang X; Huang J; Wang S; Yao Q; Li H
    Front Nutr; 2022; 9():1043901. PubMed ID: 36712521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations of metabolic dysfunction-associated fatty liver disease and hepatic fibrosis with bone mineral density and risk of osteopenia/osteoporosis in T2DM patients.
    Zhang W; Li Y; Li S; Zhou J; Wang K; Li Z; Chen N; Chen X
    Front Endocrinol (Lausanne); 2023; 14():1278505. PubMed ID: 38116314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic-associated fatty liver disease and the risk of cardiovascular disease.
    Zhang P; Dong X; Zhang W; Wang S; Chen C; Tang J; You Y; Hu S; Zhang S; Wang C; Wen W; Zhou M; Tan T; Qi G; Li L; Wang M
    Clin Res Hepatol Gastroenterol; 2023 Jan; 47(1):102063. PubMed ID: 36494073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of Non-invasive Fibrosis Scores for Predicting Advanced Fibrosis in Metabolic-associated Fatty Liver Disease.
    Chen X; Goh GB; Huang J; Wu Y; Wang M; Kumar R; Lin S; Zhu Y
    J Clin Transl Hepatol; 2022 Aug; 10(4):589-594. PubMed ID: 36062270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-invasive Screening of Metabolic Associated Fatty Liver Disease and Affecting Factors in Primary Care.
    Balci IC; Haciagaoglu N; Oner C; Cetin H; Simsek EE
    J Coll Physicians Surg Pak; 2023 Apr; 33(4):390-395. PubMed ID: 37190709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of nonalcoholic fatty liver disease (NAFLD) related steatosis indices in metabolic associated fatty liver disease (MAFLD) and comparison of the diagnostic accuracy between NAFLD and MAFLD.
    Chen J; Mao X; Deng M; Luo G
    Eur J Gastroenterol Hepatol; 2023 Apr; 35(4):394-401. PubMed ID: 36695773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dietary Quality and Relationships with Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) among United States Adults, Results from NHANES 2017-2018.
    Tian T; Zhang J; Xie W; Ni Y; Fang X; Liu M; Peng X; Wang J; Dai Y; Zhou Y
    Nutrients; 2022 Oct; 14(21):. PubMed ID: 36364767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identifying inflammatory bowel disease patients at risk of metabolic dysfunction-associated fatty liver disease: usefulness of non-invasive steatosis predictive scores.
    Capela TL; Silva VM; Freitas M; Arieira C; Gonçalves TC; de Castro FD; Magalhães J; Cotter J
    BMC Gastroenterol; 2023 Dec; 23(1):437. PubMed ID: 38093213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of five hepatic steatosis algorithms in metabolic-associated fatty liver disease: A population based study.
    Liu Y; Liu S; Huang J; Zhu Y; Lin S
    J Gastroenterol Hepatol; 2022 May; 37(5):938-945. PubMed ID: 35174539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between hepatic steatosis and fibrosis indices and dietary habits, physical activity, and quality of life.
    Vachliotis ID; Vasiloglou MF; Kapama A; Matsagkos D; Goulas A; Papaioannidou P; Polyzos SA
    Arab J Gastroenterol; 2022 Nov; 23(4):277-287. PubMed ID: 35927197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between the composite dietary antioxidant index and metabolic dysfunction-associated steatotic liver disease in adults: a cross-sectional study from NHANES 2017-2020.
    Yang Z; Song S; Li L; Yuan Z; Li Y
    Sci Rep; 2024 Jun; 14(1):13801. PubMed ID: 38877074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between Serum Ferritin Levels and Metabolic-associated Fatty Liver Disease in Adults: a Cross-sectional Study Based on the NHANES.
    Li JH; Ma XY; Yi Y; Li LR; Xu ZY; Chang Y
    Curr Med Sci; 2024 Jun; 44(3):494-502. PubMed ID: 38748368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD.
    Yamamura S; Eslam M; Kawaguchi T; Tsutsumi T; Nakano D; Yoshinaga S; Takahashi H; Anzai K; George J; Torimura T
    Liver Int; 2020 Dec; 40(12):3018-3030. PubMed ID: 32997882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of conventional non-invasive fibrosis scoring systems in patients with metabolic associated fatty liver disease.
    Wu YL; Kumar R; Wang MF; Singh M; Huang JF; Zhu YY; Lin S
    World J Gastroenterol; 2021 Sep; 27(34):5753-5763. PubMed ID: 34629799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discrepancies between Nonalcoholic and Metabolic-associated Fatty Liver Disease by Multiple Steatosis Assessment.
    Shao C; Ye J; Li X; Lin Y; Feng S; Liao B; Wang W; Gong X; Zhong B
    J Clin Transl Hepatol; 2022 Dec; 10(6):1013-1026. PubMed ID: 36381107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and risk factors of metabolic associated fatty liver disease among people living with HIV in China.
    Liu D; Shen Y; Zhang R; Xun J; Wang J; Liu L; Steinhart C; Chen J; Lu H
    J Gastroenterol Hepatol; 2021 Jun; 36(6):1670-1678. PubMed ID: 33140878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.